Calamos Advisors LLC Purchases 3,483 Shares of ADMA Biologics Inc $ADMA

Calamos Advisors LLC raised its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 0.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 537,320 shares of the biotechnology company’s stock after purchasing an additional 3,483 shares during the quarter. Calamos Advisors LLC owned approximately 0.23% of ADMA Biologics worth $9,785,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ADMA. Envestnet Asset Management Inc. raised its position in shares of ADMA Biologics by 14.5% in the first quarter. Envestnet Asset Management Inc. now owns 68,686 shares of the biotechnology company’s stock valued at $1,363,000 after purchasing an additional 8,682 shares during the period. Cerity Partners LLC grew its stake in ADMA Biologics by 10.6% in the 1st quarter. Cerity Partners LLC now owns 47,703 shares of the biotechnology company’s stock valued at $946,000 after buying an additional 4,575 shares in the last quarter. New York State Common Retirement Fund raised its holdings in ADMA Biologics by 12.5% during the 1st quarter. New York State Common Retirement Fund now owns 274,419 shares of the biotechnology company’s stock valued at $5,444,000 after acquiring an additional 30,400 shares during the period. CWM LLC lifted its position in shares of ADMA Biologics by 58.1% during the first quarter. CWM LLC now owns 18,653 shares of the biotechnology company’s stock worth $370,000 after acquiring an additional 6,855 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS lifted its position in shares of ADMA Biologics by 45.1% during the first quarter. Kornitzer Capital Management Inc. KS now owns 47,870 shares of the biotechnology company’s stock worth $950,000 after acquiring an additional 14,870 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $28.50.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $15.70 on Friday. The company’s 50 day simple moving average is $15.26 and its two-hundred day simple moving average is $17.72. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67. The stock has a market capitalization of $3.75 billion, a PE ratio of 18.26 and a beta of 0.40.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm had revenue of $134.22 million during the quarter, compared to analyst estimates of $131.20 million. During the same period in the previous year, the business earned $0.15 EPS. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. ADMA Biologics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.